

## STENTYS shares eligible for new *PEA-PME* savings plan

**PRINCETON, N.J. and PARIS - March 31, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only Self-Apposing<sup>®</sup> stent to treat acute myocardial infarction (AMI), today confirmed that its shares are eligible for the new "PEA-PME" SME equity savings plan.**

STENTYS meets the eligibility criteria for "PEA-PME" SME equity savings plans in compliance with [Decree n° 2014-283](#) issued on March 4, 2014 relating to the application of article 70 of the 2014 finance law n° 2013-1278:

- workforce of less than 5,000 employees;
- annual revenues of less than €1,500m or a balance sheet of less than €2,000m.

Investors can include STENTYS shares in PEA-PME savings accounts, a new plan aimed at encouraging investments in small and mid-cap companies:

- identical terms and conditions for opening a new account as the existing equity savings plan (PEA) accounts;
- ceiling set at €75,000
- individuals can hold *PEA-PME* savings account in a different financial institution than where they hold an existing *PEA* account;
- same tax incentives as PEA equity savings plan.

### **About the STENTYS Self-Apposing<sup>®</sup> Stent**

The STENTYS Self-Apposing<sup>®</sup> Stent addresses the stent-sizing dilemma that cardiologists are confronted with when treating heart attack patients or patients with atypical artery anatomy. Its flexible, self expanding design takes the shape of the patient's unique vessel anatomy and apposes to the irregular contours of a blood vessel, in particular after an AMI as the vessel dilates and the clot dissolves. It reduces the risk of malapposition and complications associated with conventional stents in this setting. The STENTYS Self-Apposing Stent has been marketed in Europe since receiving CE Mark in 2010. The STENTYS Sirolimus-eluting stent is expected to receive CE Mark in H2 2014.

### **About STENTYS**

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS's Self-Apposing<sup>®</sup> Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents.

**More information is available at [www.stentys.com](http://www.stentys.com).**

#### **STENTYS**

Stanislas Piot  
CFO  
Tel.: +33 (0)1 44 53 99 42  
[stan.p@stentys.com](mailto:stan.p@stentys.com)

STENTYS is listed on Comp. B of Euronext Paris  
ISIN: FR0010949404 – Ticker: STNT

#### **NewCap.**

Financial Communication / Investor Relations  
Dusan Oresansky / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 93  
[stentys@newcap.fr](mailto:stentys@newcap.fr)

#### **US: MacDougall Biomedical Communications**

Charles Liles, Tel.: 781 235 3060  
Christine Labaree or Hunter Marshall, Tel.: 650 339 7533  
[stentys@macbiocom.com](mailto:stentys@macbiocom.com)